Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 03, 2017 15:39 ET | Source: Qu Biologics

Qu Biologics Discovers Correlation Between Patient Genetics and Response to Immunotherapy in Inflammatory Bowel Disease

VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 3, 2017) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the body's...
October 13, 2016 20:31 ET | Source: Qu Biologics

Qu Biologics Publishes Promising Paper on Novel Treatment for Allergic Airway Disease

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Oct. 13, 2016) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the body's...
April 12, 2016 11:30 ET | Source: Qu Biologics

Qu Biologics Closes Private Financing of CDN$4 Million

VANCOUVER, BRITISH COLUMBIA--(Marketwired - April 12, 2016) - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body's...
April 06, 2016 10:30 ET | Source: Qu Biologics

Qu Biologics Awarded Genome BC Funding to Study QBECO Site Specific Immunomodulator (SSI) for Ulcerative Colitis

VANCOUVER, BRITISH COLUMBIA--(Marketwired - April 6, 2016) - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body's...
March 21, 2016 08:30 ET | Source: Qu Biologics

Qu Biologics Announces Initial Results in Randomized, Placebo-Controlled Crohn's Disease Clinical Trial

VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 21, 2016) - Qu Biologics Inc., an immunotherapy company developing Site Specific Immunomodulators (SSIs) for cancer and other inflammatory...
December 23, 2015 09:05 ET | Source: Qu Biologics

Qu Biologics Closes Oversubscribed Financing; Crohn's Disease Phase 2 Clinical Trial Results in First Quarter 2016

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 23, 2015) - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body's...
November 24, 2015 08:20 ET | Source: Qu Biologics

Qu Biologics Completes Enrollment of Randomized Clinical Trial in Crohn's Disease

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 24, 2015) - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune...
November 17, 2015 17:20 ET | Source: Qu Biologics

Qu Biologics Granted Three New Patents for Treating Inflammatory Bowel Disease, Colon Cancer and Skin Cancer

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 17, 2015) - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune...
September 29, 2015 09:00 ET | Source: Qu Biologics

Qu Biologics Granted U.S. Patent for Use of Staphylococcus Aureus-Based Immunotherapies to Treat Melanoma

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sept. 29, 2015) - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune...
August 31, 2015 09:00 ET | Source: Qu Biologics

Qu Biologics Opens Additional Ulcerative Colitis Clinical Trial Sites in Edmonton and Hamilton

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Aug. 31, 2015) - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune...

Next Page keyboard_arrow_right